How and Why Progression Happens
Many ALK+ NSCLC tumors initially respond to ALK inhibitor therapy, but then develop changes that allow them to continue to grow despite treatment. When this resistance to therapy happens, the disease can progress.
If your disease has progressed while taking an ALK inhibitor therapy, talk to your doctor about other treatment options available to you, including LORBRENA®.
Monitoring Disease Progression
Whether or not your lung cancer has continued to progress, life with ALK+ NSCLC may seem to center around waiting: When is the next scan? What are the next scan results going to be? Will the cancer progress? These constant concerns, sometimes referred to as “scanxiety,” may be overwhelming.
Thanks to breakthroughs in NSCLC research, there is a biomarker-driven treatment approved for use in people whose disease has progressed after they had received alectinib or ceritinib, or crizotinib and at least 1 other ALK inhibitor medicine.
ALK=anaplastic lymphoma kinase; NSCLC=non-small cell lung cancer.